Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J S Kalus

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Connecticut Medicine|November 13, 2001
A comprehensive review of antihypertensive agents providing renal protectionJ S Kalus, C M White
The Annals of Pharmacotherapy|May 11, 2001
Calcium-channel antagonists and nitrates in coronary artery bypass patients receiving radial artery graftsJ S Kalus, C A Lober
The Annals of Pharmacotherapy|February 11, 2000
Dofetilide: a class III-specific antiarrhythmic agentJ S Kalus, V F Mauro
Pharmacotherapy|November 23, 2001
Enoxaparin should be used cautiously in patients with end-stage renal diseaseJ S Kalus, A P Spencer
Diabetic Medicine : a Journal of the British Diabetic Association|March 21, 2007
Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysisD L Jennings, J S Kalus, C I Coleman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Connecticut Medicine|November 13, 2001
A comprehensive review of antihypertensive agents providing renal protectionJ S Kalus, C M White
The Annals of Pharmacotherapy|May 11, 2001
Calcium-channel antagonists and nitrates in coronary artery bypass patients receiving radial artery graftsJ S Kalus, C A Lober
The Annals of Pharmacotherapy|February 11, 2000
Dofetilide: a class III-specific antiarrhythmic agentJ S Kalus, V F Mauro
Pharmacotherapy|November 23, 2001
Enoxaparin should be used cautiously in patients with end-stage renal diseaseJ S Kalus, A P Spencer
Diabetic Medicine : a Journal of the British Diabetic Association|March 21, 2007
Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysisD L Jennings, J S Kalus, C I Coleman, et al.
Pageof 1